Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in Psoriasis : A Systematic Review and Drug-Response Meta Analysis of RCTs. JIMKI [Internet]. 2025 Dec. 10 [cited 2026 May 30];:10. Available from: https://jimki.bapin.or.id/main/article/view/961